Scholarlink

<p>Tree pollen allergies, particularly those caused by members of the Betulaceae family such as birch, alder, and hazel, are widespread and represent a&#xa0;significant burden on the healthcare system, with prevalence rates of 15–30%. Clinical presentation consists predominantly of allergic rhinitis or rhinoconjunctivitis, which can progress to allergic asthma. Allergen immunotherapy (AIT), through the induction of immunological tolerance to the triggering allergen, represents the only currently available disease-modifying treatment option for tree pollen allergy. In addition to subcutaneous immunotherapy (SCIT), sublingual immunotherapy (SLIT) in particular has established itself as an effective and safe therapy. Current randomized trials and real-world data demonstrate a&#xa0;significant reduction in symptoms in both adults and children, as well as evidence for the prevention of asthma development. Molecular insights into tree pollen allergens and advances in component-based diagnostics are enabling more precise patient selection and treatment optimization. Of particular importance here is the differentiation between an allergy to the major allergen of birch and homologous allergens of other tree species that show little or no cross-reactivity. The current findings on the diagnosis and treatment of tree pollen allergy are reviewed in this article.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Allergen immunotherapy for tree pollen allergy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月7日

查看全文
  • Felix Klimek,
  • Friederike Bärhold,
  • Charlotte Rott,
  • Katharina Bremerich,
  • Ludger Klimek,
  • Christoph Bergmann,
  • Jan Hagemann,
  • Mandy Cuevas,
  • Paolo Matricardi,
  • Sven Becker

摘要

Tree pollen allergies, particularly those caused by members of the Betulaceae family such as birch, alder, and hazel, are widespread and represent a significant burden on the healthcare system, with prevalence rates of 15–30%. Clinical presentation consists predominantly of allergic rhinitis or rhinoconjunctivitis, which can progress to allergic asthma. Allergen immunotherapy (AIT), through the induction of immunological tolerance to the triggering allergen, represents the only currently available disease-modifying treatment option for tree pollen allergy. In addition to subcutaneous immunotherapy (SCIT), sublingual immunotherapy (SLIT) in particular has established itself as an effective and safe therapy. Current randomized trials and real-world data demonstrate a significant reduction in symptoms in both adults and children, as well as evidence for the prevention of asthma development. Molecular insights into tree pollen allergens and advances in component-based diagnostics are enabling more precise patient selection and treatment optimization. Of particular importance here is the differentiation between an allergy to the major allergen of birch and homologous allergens of other tree species that show little or no cross-reactivity. The current findings on the diagnosis and treatment of tree pollen allergy are reviewed in this article.